Spotlight Correspondence
Leukemia (2005) 19, 1267–1269. doi:10.1038/sj.leu.2403775 Published online 28 April 2005
Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies
C Gambacorti-Passerini1,2, M Gasser3,4, S Ahmed4, S Assouline2 and L Scapozza4
- 1University of Milano Bicocca and National Cancer Institute, Milan, Italy
- 2Department of Oncology, McGill University, Montreal, Canada
- 3Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH), Zurich, Switzerland
- 4Laboratoire de Chimie Thérapeutique, School of Pharmaceutical Sciences, Geneva University, Genève, Switzerland
Correspondence: Prof. L Scapozza, Laboratoire de Chimie Thérapeutique, School of Pharmaceutical Sciences, University of Geneva, Quai Ernest-Ansermet 30, 1211 Genève 4, Switzerland. Fax: +41 22 379 3360; E-mail: leonardo.scapozza@pharm.unige.ch
Received 4 March 2005; Accepted 17 March 2005; Published online 28 April 2005.
Top of page
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
